FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2271-2281 May 31, 2007 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.

Methods In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group.

Results Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P<0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02).

Conclusions As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov] .)

Source Information

From the Fox Chase Cancer Center, Philadelphia (G.H.); Sidney Kimmel Comprehensive Cancer Center, Baltimore (M.C.); Klinika Onkologii, Oddzial Chemioterapii, Pozna, Poland (P.T.); Our Lady of Mercy Medical Center, Bronx, NY (J.D.); University of California, Los Angeles, Los Angeles (R.F.); McMaster University, Hamilton, ON, Canada (A.K.); Lublin Oncological Center, Lublin, Poland (E.S.); Vanderbilt University Medical Center, Nashville (J.S.); Beth Israel Deaconess Medical Center, Boston (D.M.); National Institute of Oncology, Budapest, Hungary (I.B.); Military Medical Academy, Belgrade, Serbia (Z.K.); Regional Clinical Center of Urology and Nephrology, Kharkov, Ukraine (V.L.); University of Bonn, Bonn, Germany (I.G.H.S.-W.); Kemerovo State Medical Academy, Regional Clinical Hospital, Kemerovo, Russia (O.B.); Ege University Medical Faculty, Izmir, Turkey (E.G.); Wyeth Research, Cambridge, MA (T.O., S.L., L.M.); and Memorial Sloan-Kettering Cancer Center, New York (R.J.M.).

Address reprint requests to Dr. Hudes at the Department of Medical Oncology, Rm. 307, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, or at gary.hudes{at}fccc.edu.

Full Text of this Article

Related Letters:

Temsirolimus for Advanced Renal-Cell Carcinoma
Fazio N., Dettori M., Lorizzo K., Ferretti G., Hudes G.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1050-1051, Sep 6, 2007. Correspondence

This article has been cited by other articles:

• Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K.C., Rock, K. L., Wu, C.-L. (2008). Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas. Clin. Cancer Res. 14: 5579-5584 [Abstract] [Full Text]  
• Crispen, P. L., Sheinin, Y., Roth, T. J., Lohse, C. M., Kuntz, S. M., Frigola, X., Thompson, R. H., Boorjian, S. A., Dong, H., Leibovich, B. C., Blute, M. L., Kwon, E. D. (2008). Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 14: 5150-5157 [Abstract] [Full Text]  
• Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19: 1387-1392 [Abstract] [Full Text]  
• Negrier, S. (2008). Temsirolimus in metastatic renal cell carcinoma. Ann Oncol 19: 1369-1370 [Full Text]  
• Boone, J, Kate, F J W T., Offerhaus, G J A, van Diest, P J, Rinkes, I H M B., van Hillegersberg, R (2008). mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?. J. Clin. Pathol. 61: 909-913 [Abstract] [Full Text]  
• Woodard, J., Sassano, A., Hay, N., Platanias, L. C. (2008). Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. Clin. Cancer Res. 14: 4640-4649 [Abstract] [Full Text]  
• Brugarolas, J., Lotan, Y., Watumull, L., Kabbani, W. (2008). Sirolimus in Metatastic Renal Cell Carcinoma. JCO 26: 3457-3460 [Full Text]  
• Trotta, F., Apolone, G., Garattini, S., Tafuri, G. (2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol 19: 1347-1353 [Abstract] [Full Text]  
• Signoretti, S., Bratslavsky, G., Waldman, F. M., Reuter, V. E., Haaga, J., Merino, M., Thomas, G. V., Pins, M. R., Libermann, T., Gillespie, J., Tomaszewski, J. E., Compton, C. C., Hruszkewycz, A., Linehan, W. M., Atkins, M. B. (2008). Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. Clin. Cancer Res. 14: 3699-3705 [Abstract] [Full Text]  
• Yang, L., Clarke, M. J., Carlson, B. L., Mladek, A. C., Schroeder, M. A., Decker, P., Wu, W., Kitange, G. J., Grogan, P. T., Goble, J. M., Uhm, J., Galanis, E., Giannini, C., Lane, H. A., James, C. D., Sarkaria, J. N. (2008). PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel. Clin. Cancer Res. 14: 3993-4001 [Abstract] [Full Text]  
• Garcia, J. A., Danielpour, D. (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Molecular Cancer Therapeutics 7: 1347-1354 [Abstract] [Full Text]  
• Wei, L. H., Su, H., Hildebrandt, I. J., Phelps, M. E., Czernin, J., Weber, W. A. (2008). Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma. Clin. Cancer Res. 14: 3416-3426 [Abstract] [Full Text]  
• Verheul, H. M.W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P., Pili, R. (2008). Combination Strategy Targeting the Hypoxia Inducible Factor-1{alpha} with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clin. Cancer Res. 14: 3589-3597 [Abstract] [Full Text]  
• Michaelson, M. D., Iliopoulos, O., McDermott, D. F., McGovern, F. J., Harisinghani, M. G., Oliva, E. (2008). Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma. NEJM 358: 2389-2396 [Full Text]  
• Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., Gores, G. J., for the Panel of Experts in HCC-Design Clinical Tr, (2008). Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 698-711 [Abstract] [Full Text]  
• Bukowski, R. M. (2008). How I Treat Renal Cell Carcinoma. J Oncol Pract 4: 150-152 [Full Text]  
• Frei, B. L., Soefje, S. A. (2008). A Review of the Cardiovascular Effects of Oncology Agents. Journal of Pharmacy Practice 21: 146-158 [Abstract]  
• O'Donnell, A., Faivre, S., Burris, H. A. III, Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., Brock, C., Jones, S., Raymond, E., Judson, I. (2008). Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors. JCO 26: 1588-1595 [Abstract] [Full Text]  
• Fraenkel, M., Ketzinel-Gilad, M., Ariav, Y., Pappo, O., Karaca, M., Castel, J., Berthault, M.-F., Magnan, C., Cerasi, E., Kaiser, N., Leibowitz, G. (2008). mTOR Inhibition by Rapamycin Prevents {beta}-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes. Diabetes 57: 945-957 [Abstract] [Full Text]  
• Waxman, J., Kenny, L., Ngan, S. (2008). New treatments for kidney cancer. BMJ 336: 681-682 [Full Text]  
• Moreno, A., Akcakanat, A., Munsell, M. F, Soni, A., Yao, J. C, Meric-Bernstam, F. (2008). Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15: 257-266 [Abstract] [Full Text]  
• Rini, B. I. (2008). Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin. Clin. Cancer Res. 14: 1286-1290 [Full Text]  
• Fojo, T. (2008). Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better. The Oncologist 13: 277-283 [Full Text]  
• Gridelli, C., Maione, P., Rossi, A. (2008). The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer. The Oncologist 13: 139-147 [Abstract] [Full Text]  
• Booth, C. M., Tannock, I. (2008). Reflections on Medical Oncology: 25 Years of Clinical Trials Where Have We Come and Where Are We Going?. JCO 26: 6-8 [Full Text]  
• Rathmell, W. K., Stadler, W. M., Rini, B. I. (2008). Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer. Am Soc Clin Oncol Ed Book 2008: 192-198 [Abstract] [Full Text]  
• Costa, L. J., Drabkin, H. A. (2007). Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. The Oncologist 12: 1404-1415 [Abstract] [Full Text]  
• Ebbinghaus, S., Hussain, M., Tannir, N., Gordon, M., Desai, A. A., Knight, R. A., Humerickhouse, R. A., Qian, J., Gordon, G. B., Figlin, R. (2007). Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Clin. Cancer Res. 13: 6689-6695 [Abstract] [Full Text]  
• Harrison, M. L., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles, K., Ahern, R., King, D. M., Eisen, T., Corringham, R., DeWitte, M., Balkwill, F., Gore, M. (2007). Tumor Necrosis Factor {alpha} As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. JCO 25: 4542-4549 [Abstract] [Full Text]  
• Kwak, E. L., Clark, J. W., Chabner, B. (2007). Targeted Agents: The Rules of Combination. Clin. Cancer Res. 13: 5232-5237 [Abstract] [Full Text]  
• Fazio, N., Dettori, M., Lorizzo, K., Ferretti, G., Hudes, G. (2007). Temsirolimus for Advanced Renal-Cell Carcinoma. NEJM 357: 1050-1051 [Full Text]  
• Ryan, C. W., Goldman, B. H., Lara, P. N. Jr, Mack, P. C., Beer, T. M., Tangen, C. M., Lemmon, D., Pan, C.-X., Drabkin, H. A., Crawford, E. D. (2007). Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. JCO 25: 3296-3301 [Abstract] [Full Text]  
• (2007). Survival Benefit from mTOR Inhibition in Advanced Kidney Cancer. JWatch Oncology and Hematology 2007: 1-1 [Full Text]